Hisamitsu Pharmaceutical (4530) Stock Overview
Manufactures and sells pharmaceuticals in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
4530 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Hisamitsu Pharmaceutical Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6,039.00 |
| 52 Week High | JP¥6,695.00 |
| 52 Week Low | JP¥3,783.00 |
| Beta | 0.15 |
| 1 Month Change | -5.64% |
| 3 Month Change | 45.10% |
| 1 Year Change | 47.36% |
| 3 Year Change | 58.71% |
| 5 Year Change | -12.60% |
| Change since IPO | 1,269.39% |
Recent News & Updates
Recent updates
What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You
Jan 06
These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely
Jan 05Does Hisamitsu Pharmaceutical (TSE:4530) Deserve A Spot On Your Watchlist?
Dec 18Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥60.00
Nov 07Hisamitsu Pharmaceutical's (TSE:4530) Earnings Are Of Questionable Quality
Oct 18Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year
Jul 25Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00
Jul 11Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00
Jun 27We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings
Apr 18With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case
Mar 07Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?
Feb 17Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00
Jan 13Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00
Dec 30Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 27Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00
Nov 08We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt
Nov 04Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations
Oct 17Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing
Sep 16Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 20Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00
Jul 26Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year
Jul 11Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00
Jun 27Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00
Jun 13Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price
Apr 09Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching
Mar 18Shareholder Returns
| 4530 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 0.1% | -7.0% | -5.4% |
| 1Y | 47.4% | 27.0% | 36.4% |
Return vs Industry: 4530 exceeded the JP Pharmaceuticals industry which returned 27% over the past year.
Return vs Market: 4530 exceeded the JP Market which returned 36.4% over the past year.
Price Volatility
| 4530 volatility | |
|---|---|
| 4530 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in JP Market | 8.7% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4530's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4530's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1847 | 2,799 | Kazue Nakatomi | www.global.hisamitsu |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders.
Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary
| 4530 fundamental statistics | |
|---|---|
| Market cap | JP¥423.17b |
| Earnings (TTM) | JP¥19.99b |
| Revenue (TTM) | JP¥159.27b |
Is 4530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4530 income statement (TTM) | |
|---|---|
| Revenue | JP¥159.27b |
| Cost of Revenue | JP¥65.22b |
| Gross Profit | JP¥94.04b |
| Other Expenses | JP¥74.06b |
| Earnings | JP¥19.99b |
Last Reported Earnings
Nov 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 285.25 |
| Gross Margin | 59.05% |
| Net Profit Margin | 12.55% |
| Debt/Equity Ratio | 0.9% |
How did 4530 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/08 10:58 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/11/30 |
| Annual Earnings | 2025/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hisamitsu Pharmaceutical Co., Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |
| Akitada Iwasa | Daiwa Securities Co. Ltd. |